You are here: / / / OvaWatch®

Redefine Ovarian Care for Adnexal Masses

OvaWatch is a non-invasive blood test intended to assess the risk of ovarian cancer in patients with an adnexal mass initially evaluated as indeterminate or benign to personalize treatment.

Refine Care from Uncertainty to Confidence

One Simple Blood Draw.

Many Benefits.

For providers actively treating women with indeterminate or benign pelvic masses, OvaWatch:

  • Provides reliable and comprehensive risk assessment scores over time
  • Delivers proprietary score with a high negative predictive value of >99%
  • Incorporates 7 total biomarkers, age, and menopausal status
  • Includes individual CA-125 and HE4 levels

Biomarker Profile

Planning for surgery?

PRECAUTION: OvaWatch is intended for use as a non-invasive test to assess the risk of ovarian cancer for women with adnexal masses, evaluated by initial clinical assessment (ICA) as indeterminate or benign. In conjunction with imaging (ultrasound and/or CT) and clinical assessment, this test will support physicians in making informed clinical decisions in the management of women with adnexal masses. The test is not intended as a screening test or a stand-alone diagnostic assay.

OvaWatch® is an offering of Aspira Women’s Health.

References:

  1. Reilly, G., Bullock, R. G., Greenwood, J., Ure, D. R., Stewart, E., Davidoff, P., … & Northrop, L. E. (2022). Analytical validation of a deep neural network algorithm for the detection of ovarian cancer. JCO Clinical Cancer Informatics, 6, e2100192.
  2. Bristow, R. E., Smith, A., Zhang, Z., Chan, D. W., Crutcher, G., Fung, E. T., & Munroe, D. G. (2013). Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecologic oncology, 128(2), 252-259.
  3. Choudhury, M. Roy, Pappas, T. C., Twiggs, L. B., Caoili, E., Fritsche, H., & Phan, R. T. (2024). Ovarian Cancer surgical consideration is markedly improved by the neural network powered-MIA3G multivariate index assay. Frontiers in Medicine, 11, 1374836.
  4. Dunton, C. J., Hutchcraft, M. L., Bullock, R. G., Northrop, L. E., & Ueland, F. R. (2021). Salvaging detection of early-stage ovarian malignancies when CA125 is not informative. Diagnostics, 11(8), 1440.
  5. ACOG Practice Bulletin Number 174, November 2016
  6. SGO Position Statement Issued 2011, Updated 2013
  7. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. 2016 Nov;128(5):e210-e226. doi: 10.1097/AOG.0000000000001768. PMID: 27776072.
  8. Castillo G, Alcázar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004; 92:965.
  9. Pavlik EJ, Ueland FR, Miller RW, et al. Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography. Obstet Gynecol 2013; 122:210.
  10. Ueland, F. R., & Fredericks, N. I. (2018). Ovarian masses: Surgery or surveillance. OBG Manag, 30(6), 17-26.
  11. Cleveland Clinic. (n.d.). Adnexal mass (tumor): Symptoms, causes & treatment. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22015-adnexal-mass-tumors
  12. Eskander, R., Berman, M., & Keder, L. (2016). Evaluation and management of adnexal masses. Obstetrics and Gynecology, 128(5), e210-e226.
  13. Alcázar, J. L., Pascual, M. A., Graupera, B., Aubá, M., Errasti, T., Olartecoechea, B., … & Guerriero, S. (2016). External validation of IOTA simple descriptors and simple rules for classifying adnexal masses. Ultrasound in Obstetrics & Gynecology, 48(3), 397-402.
  14. Kingsberg, S. A., Larkin, L. C., & Liu, J. H. (2020). Clinical effects of early or surgical menopause. Obstetrics & Gynecology, 135(4), 853-868.